A5000873286- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Bone health and treatments
- Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Protein Degradation and Inhibitors
- Immunodeficiency and Autoimmune Disorders
- Bone Metabolism and Diseases
- SARS-CoV-2 and COVID-19 Research
- Peptidase Inhibition and Analysis
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Systemic Lupus Erythematosus Research
- Monoclonal and Polyclonal Antibodies Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Renal Diseases and Glomerulopathies
- Platelet Disorders and Treatments
- Blood groups and transfusion
- Cell Adhesion Molecules Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Hepatitis C virus research
- Chronic Myeloid Leukemia Treatments
- COVID-19 Clinical Research Studies
- HIV/AIDS drug development and treatment
- Inflammasome and immune disorders
University of Bari Aldo Moro
2014-2025
Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari
2012-2023
Fondazione Gimema Onlus
2009-2019
Institute of Physics
2002-2005
University of Foggia
2002-2004
Institute of Crystallography
2002
Argonne National Laboratory
2002
Indian Institute of Science Bangalore
2002
University of Milan
1982-1991
National Institutes of Health
1990-1991
Wingless-type (Wnt) signaling through the secretion of Wnt inhibitors Dickkopf1, soluble frizzled-related protein-2 and -3 has a key role in decreased osteoblast (OB) activity associated with multiple myeloma (MM) bone disease. We provide evidence that another antagonist, sclerostin, an osteocyte-expressed negative regulator formation, is expressed by cells, is, human cell lines (HMCLs) plasma cells (CD138+ cells) obtained from marrow (BM) large number MM patients demonstrated BM stromal...
In a phase II trial, we evaluated chlorambucil and rituximab (CLB‐R) as first‐line induction treatment with or without R maintenance for elderly chronic lymphocytic leukemia (CLL) patients. Treatment consisted of eight 28‐day cycles CLB (8 mg/m 2 /day, days 1–7) (day 1 cycle 3, 375 ; 4–8, 500 ). Responders were randomized to 12 8‐week doses (375 ) observation. As per intention‐to‐treat analysis, 82.4% (95% CI, 74.25–90.46%) 85 patients achieved an overall response (OR), 16.5% complete (CR),...
Sclerostin, an osteocyte‐expressed negative regulator of bone formation, is one the inhibitors Wnt signaling that a critical pathway in correct process osteoblast differentiation. It has been demonstrated through secretion inhibitors, such as DKK1, sFRP‐2, and sFRP‐3, plays key role decreased activity associated with multiple myeloma (MM) disease. We provide evidence sclerostin expressed by cells are human cell lines plasma (CD138 + cells) obtained from marrow (BM) large number MM patients...
Schnitzler syndrome is characterized by an urticarial rash, a monoclonal gammopathy, and clinical, histological, biological signs of neutrophil-mediated inflammation. The aim this study was to assess the applicability validity existing diagnostic criteria in real-life patients.This multicentric conducted between 2009 2014 14 hospitals which patients with or controls related disorders were followed up. We compared sensitivities specificities calculated positive negative predictive values...
Hereditary hemorrhagic telangiectasia (HHT) is a genetic angiodysplasia affecting multiple organs. Two genes involved in the transduction of TGF-beta signalling are responsible for HHT. An additional role vascular endothelial growth factor (VEGF) has been proposed. Serum VEGF, which evaluated several diseases characterized by aberrant angiogenesis, never measured patients with HHT.To evaluate VEGF serum levels HHT as compared to normal subjects.32 (age 47.7 +/- 16.7 years) and control group...
// Giacomina Brunetti 1, * , Rita Rizzi 2, Angela Oranger 1 Isabella Gigante Giorgio Mori 3 Grazia Taurino Teresa Mongelli Graziana Colaianni Adriana Di Benedetto Roberto Tamma Giuseppe Ingravallo 4 Anna Napoli Maria Felicia Faienza 5 Mestice 2 Paola Curci Giorgina Specchia Silvia Colucci Grano Department of Basic and Medical Sciences, Neurosciences Sense Organs, section Human Anatomy Histology, University Bari, Italy Emergency Organ Transplantation, Section Hematology with Clinical...
Key Points Daratumumab is effective in treated light chain deposition disease. can prevent progression of renal failure these patients.
In the past, hemlock poisoning was only known for its neurotoxic effects; quite recently non-neurological features, consisting of rhabdomyolysis and acute renal failure, have been also described. Here we report our experience with these clinical findings, which frequently observe in accidental poisoning. Between 1972 1990 studied 18 patients: 17 them were poisoned by conline (an alkaloid Conium maculatim) Apulia (Italy), one cicutoxin (the active principle water hemlock) New Mexico (USA)....
In the ELOQUENT-3 trial, combination of elotuzumab, pomalidomide and dexamethasone (EloPd) proved a superior clinical benefit over Pd with manageable toxicity profile, leading to its approval in relapsed/refractory multiple myeloma (RRMM), who had received at least two prior therapies, including lenalidomide proteasome inhibitor (PI). We report here real-world experience 200 RRMMs treated EloPd 35 Italian centers outside trials. our dataset, median number lines therapy was 2, 51% cases...
ABSTRACT Tumor necrosis factor superfamily member 14 (TNFSF14), LIGHT, is a component of the cytokine network that regulates innate and adaptive immune responses, which promote homeostasis lymphoid organs, liver, bone. Metastatic tumors often disrupt tissue microenvironment, thus altering invaded organ; however, underlying mechanisms required further studies. We investigated role LIGHT in osteolytic bone disease induced by metastatic non-small cell lung cancer (NSCLC). Patients diagnosed...